Trends in Anemia Management Practices in Patients Receiving Hemodialysis and Peritoneal Dialysis: A Retrospective Cohort Analysis

American Journal of Nephrology

Volumn 41, Issue 4-5, 2015, Pages 354-361

  Wetmore, James B ^a,b   Peng, Yi ^a   Monda, Keri L ^c   Kats, Allyson M ^a   Kim, Deborah H ^c   Bradbury, Brian D ^c   Collins, Allan J ^a,d   Gilbertson, David T ^a  

^a MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

^b HENNEPIN COUNTY MEDICAL CENTER   (United States)

^c AMGEN INC   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Anemia; Dialysis; ESRD; Hemodialysis; Hemoglobin; Peritoneal dialysis

Indexed keywords

ANTIANEMIC AGENT; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN; IRON;

ANEMIA; ARTICLE; DRUG DOSE REDUCTION; ERYTHROCYTE TRANSFUSION; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PERITONEAL DIALYSIS; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREND STUDY; ADOLESCENT; ADULT; AGED; CLINICAL PRACTICE; COHORT ANALYSIS; COMPLICATION; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; RENAL REPLACEMENT THERAPY; STATISTICS AND NUMERICAL DATA; TRENDS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANEMIA; COHORT STUDIES; EPOETIN ALFA; ERYTHROCYTE TRANSFUSION; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; IRON; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; PRACTICE PATTERNS, PHYSICIANS'; RENAL DIALYSIS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84937966737     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000431335     Document Type: Article

References (30)

1. Eschbach JW, Adamson JW: Anemia of endstage renal disease (ESRD). Kidney Int 1985; 28: 1-5.
2. Churchill DN, Muirhead N, Goldstein M, Posen G, Fay W, Beecroft ML, Gorman J, Taylor DW: Effect of recombinant human erythropoietin on hospitalization of hemodialysis patients. Clin Nephrol 1995; 43: 184-188.
3. US Renal Data System: USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2013.
4. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590.
5. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098.
6. Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084.
7. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032.
8. Department of Health and Human Services, Centers for Medicare and Medicaid Services. 42 CFR Parts 410, 413 and 414; Medicare Program; End-stage Renal Disease Prospective Payment System; Final Rule and Proposed Rule, 2010. http://www.gpo.gov/ (accessed April 13, 2015).
9. Collins AJ: ESRD Payment Policy Changes: The New 'Bundled' Dialysis Prospective Payment System (PPS) in the United States, 2012. http://www.usrds.org/2012/pres/USDialysis-Bundle-impact-NKFCM2012.pdf (accessed April 13, 2015).
10. Thakuria M, Ofsthun NJ, Mullon C, Diaz-Buxo JA: Anemia management in patients receiving chronic hemodialysis. Semin Dial 2011; 24: 597-602.
11. Kliger AS, Foley RN, Goldfarb DS, Goldstein SL, Johansen K, Singh A, Szczech L: KDOQI US commentary on the 2012 KDIGO clinical practice guideline for anemia in CKD. Am J Kidney Dis 2013; 62: 849-859.
12. Kidney Disease; Improving Global Outcomes: KDIGO clinical practice guidelines for anemia in chronic kidney disease. Kidney Int Suppl 2012; 2: 279-335.
13. Charytan C: Bundled-rate legislation for Medicare reimbursement for dialysis services: implications for anemia management with ESAs. Clin J Am Soc Nephrol 2010; 5: 2355-2362.
14. Locatelli F, Del Vecchio L: An expert opinion on the current treatment of anemia in patients with kidney disease. Expert Opin Pharmacother 2012; 13: 495-503.
15. Singh N, Agarwal AK: Pumping iron: revisiting risks, benefits and strategies in treatment of iron deficiency in end-stage renal disease. Clin Nephrol 2012; 77: 188-194.
16. Hörl WH: Anaemia management and mortality risk in chronic kidney disease. Nat Rev Nephrol 2013; 9: 291-301.
17. Macdougall IC, Obrador GT: How important is transfusion avoidance in 2013? Nephrol Dial Transplant 2013; 28: 1092-1099.
18. Gilbertson DT, Monda KL, Bradbury BD, Collins AJ: RBC transfusions among hemodialysis patients (1999-2010): influence of hemoglobin concentrations below 10 g/dl. Am J Kidney Dis 2013; 62: 919-928.
19. Gill KS, Muntner P, Lafayette RA, Petersen J, Fink JC, Gilbertson DT, Bradbury BD: Red blood cell transfusion use in patients with chronic kidney disease. Nephrol Dial Transplant 2013; 28: 1504-1515.
20. Liu J, Huang Z, Gilbertson DT, Foley RN, Collins AJ: An improved comorbidity index for outcome analyses among dialysis patients. Kidney Int 2010; 77: 141-151.
21. Liu J, Louis TA, Pan W, Ma JZ, Collins AJ: State-level adjusted ESRD incident rates: use of observed vs model-predicted categoryspecific rates. Kidney Int 2006; 69: 1459-1463.
22. Collins AJ, Monda KL, Molony JT, Li S, Gilbertson DT, Bradbury BD: Effect of facility-level hemoglobin concentration on dialysis patient risk of transfusion. Am J Kidney Dis 2014; 63: 997-1006.
23. Yabu JM, Anderson MW, Kim D, Bradbury BD, Lou CD, Petersen J, Rossert J, Chertow GM, Tyan DB: Sensitization from transfusion in patients awaiting primary kidney transplant. Nephrol Dial Transplant 2013; 28: 2908-2918.
24. Leffell MS, Kim D, Vega RM, Zachary AA, Petersen J, Hart JM, Rossert J, Bradbury BD: Red blood cell transfusions and the risk of allosensitization in patients awaiting primary kidney transplantation. Transplantation 2014; 97: 525-533.
25. Cardarelli F, Pascual M, Tolkoff-Rubin N, Delmonico FL, Wong W, Schoenfeld DA, Zhang H, Cosimi AB, Saidman SL: Prevalence and significance of anti-HLA and donor-specific antibodies long-term after renal transplantation. Transpl Int 2005; 18: 532-540.
26. Balasubramaniam GS, Morris M, Gupta A, Mesa IR, Thuraisingham R, Ashman N: Allosensitization rate of male patients awaiting first kidney grafts after leuko-depleted blood transfusion. Transplantation 2012; 93: 418-422.
27. Opelz G: Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies. Lancet 2005; 365: 1570-1576.
28. Silverberg DS, Wexler D, Iaina A, Steinbruch S, Wollman Y, Schwartz D: Anemia, chronic renal disease and congestive heart failure-the cardio renal anemia syndrome: the need for cooperation between cardiologists and nephrologists. Int Urol Nephrol 2006; 38: 295-310.
29. Efstratiadis G, Konstantinou D, Chytas I, Vergoulas G: Cardio-renal anemia syndrome. Hippokratia 2008; 12: 11-16.
30. Khawar O, Kalantar-Zadeh K, Lo WK, Johnson D, Mehrotra R: Is the declining use of longterm peritoneal dialysis justified by outcome data? Clin J Am Soc Nephrol 2007; 2: 1317-1328.